Showing results (231-240 of 277) with videos related to
Sort By:
Pageof 28
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.Lancet (London, England)|July 9, 2019
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trialKristian Reich, Melinda Gooderham, Diamant Thaçi, et al.The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.JAMA Dermatology|April 6, 2013
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional studyAmy S Paller, Katherine Mercy, Mary J Kwasny, et al.Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.Nature Genetics|November 11, 2003
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasisCynthia Helms, Li Cao, James G Krueger, et al.Pageof 28